DiaMedica Therapeutics (NASDAQ:DMAC) Share Price Breaks Below Fifty Day Moving Average - Here's What Happened

DiaMedica Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • DiaMedica shares fell below their 50-day moving average, trading as low as $7.99 and last at $8.02, versus a 50-day average of $8.35.
  • Analyst opinions are mixed: the consensus rating is Hold with a $12 price target, while Wall Street Zen downgraded the stock to Sell and HC Wainwright maintained a Buy rating.
  • The company reported quarterly earnings per share of -$0.21, matching the consensus estimate; institutional investors own about 10.12% of its shares.
  • MarketBeat previews top five stocks to own in December.

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $8.35 and traded as low as $7.99. DiaMedica Therapeutics shares last traded at $8.02, with a volume of 375,716 shares traded.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wall Street Zen lowered shares of DiaMedica Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, November 14th. HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of DiaMedica Therapeutics in a report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $12.00.

Check Out Our Latest Analysis on DiaMedica Therapeutics

DiaMedica Therapeutics Stock Performance

The firm has a market capitalization of $432.76 million, a P/E ratio of -10.55 and a beta of 0.95. The firm has a 50 day simple moving average of $8.35 and a two-hundred day simple moving average of $7.20.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). Sell-side analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of institutional investors have recently added to or reduced their stakes in DMAC. Goldman Sachs Group Inc. grew its position in DiaMedica Therapeutics by 11.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 187,465 shares of the company's stock worth $1,550,000 after purchasing an additional 19,399 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $1,023,000. Bank of New York Mellon Corp bought a new position in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $829,000. Sei Investments Co. boosted its stake in shares of DiaMedica Therapeutics by 100.0% in the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company's stock worth $754,000 after buying an additional 55,660 shares during the last quarter. Finally, AWM Investment Company Inc. boosted its stake in shares of DiaMedica Therapeutics by 80.8% in the 3rd quarter. AWM Investment Company Inc. now owns 65,097 shares of the company's stock worth $538,000 after buying an additional 29,097 shares during the last quarter. 10.12% of the stock is owned by institutional investors.

About DiaMedica Therapeutics

(Get Free Report)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DiaMedica Therapeutics Right Now?

Before you consider DiaMedica Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.

While DiaMedica Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines